

Bone Metabolism and Fracture Risk in Diabetes Mellitus

Melisa Puspitasari,¹ Dyah Purnamasari,² Bambang Setyohadi,³ Harry Isbagio³

¹Department of Internal Medicine, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia

²Division of Metabolism and Endocrinology, Department of Internal Medicine, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia

³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Abstract

Individuals with Type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) are at increased risk for fragility fractures. Bone mineral density (BMD) is decreased in T1DM but often normal or even elevated in T2DM when compared with age-matched non-DM populations. However, bone turnover is decreased in both T1DM and T2DM. The pathophysiologic mechanisms leading to bone fragility is multifactorial, and potentially leads to reduced bone formation, altered bone microstructure and decreased bone strength. Interestingly, different antidiabetic treatments may influence fracture risk due to effects on glycemic control, triggering of hypoglycemic events or osteoblastogenesis.

Key words: bone metabolism, diabetes mellitus, bone remodeling, biomarkers

INTRODUCTION

Diabetes mellitus (DM) is a chronic metabolic non-communicable disease with increasing global prevalence. By 2015, there were over 415 million adults living with DM, and this number is expected to increase to 642 million by 2040.¹ Apart from the major DM-related complications such as cardiovascular diseases, osteoporotic fracture is increasingly recognized as an important complication of type 1 DM (T1DM) and type 2 DM (T2DM) in both men and women.² Worldwide, over 9 million osteoporotic fractures occur annually, and the effect of reduced bone mineral density (BMD), including osteoporosis, is predicted to result in over 5 million disability adjusted life years (DALY) and 188,000 deaths each year. The incidence of hip fractures in individuals with T1DM was 383 per 100,000, six-fold higher than the overall incidence of hip fracture in the age-matched, non-diabetic population.³ The odds ratio of vertebral fracture in T2DM was 1,86 and 4,73 in women and men,⁴ respectively, with a relative risk of 1,83 (95% CI: 1,25-1,53).⁵ These studies were largely done using the cross-sectional design and showed only associations rather than causality of DM and the incidence of fracture. However, taken together, these data indeed show the increased fracture risk in individuals with DM. The presence of microvascular complications in DM have also been associated with reduction of BMD in T1DM⁵ and with bone micro-architectural abnormalities in T2DM.⁶⁻⁹

Increasing evidence shows the interaction between plasma glucose levels and bone metabolism, revealing mechanisms through which bone fragility may develop in DM. Whether this interaction translates into increased risk for fragility fractures and decreased BMD in all DM populations remains unclear. Studies reported conflicting findings of changes in BMD. Whereas BMD is decreased in T1DM,¹⁰⁻¹⁵ it is either increased or unchanged in T2DM.¹⁶⁻²¹ Intriguingly, a meta-analysis found that both DM types are associated with increased risk of hip fracture.² In this review, we discuss bone metabolism and remodeling, the pathophysiologic mechanisms by which bone fragility may occur in DM, and the effects of glucose-lowering drugs on bone health.

Bone Metabolism and Remodeling

The structural components of bone consist of a largely mineralized extracellular matrix, collagen, and cells. Bone is a living organ that is continuously being remodeled, in a process that involves a balance in the tearing down of bone structure (bone resorption) and its rebuilding (bone formation). This resorption and formation allows for the repair of micro-fractures and the modification of structure in response to stress.²² Bone resorption is initiated by osteoclasts, which attach to bone surface and secrete acid and hydrolytic enzymes that resorb bone, releasing minerals and collagen fragments.²³ After osteoclastic

eISSN 2308-118x

Printed in the Philippines

Copyright © 2017 by the JAFES

Received: August 28, 2017. Accepted: September 30, 2017.

<https://doi.org/10.15605/jafes.032.02.14>

Corresponding author: Dyah Purnamasari, MD

Staff, Division of Metabolism and Endocrinology

Department of Internal Medicine, Faculty of Medicine

University of Indonesia, Cipto Mangunkusumo Hospital

Jl. Salemba 6 Jakarta 10430, Indonesia

Tel. No.: 021-3907703

Fax No: 021-3928658/9

E-mail address: dyah_p_irawan@yahoo.com

resorption is completed, a reversal phase takes place in which mononuclear cells prepare the bone surface for new osteoblasts to begin bone formation by laying down a layer of glycoprotein-rich material to which the osteoblasts can adhere.²⁴ Bone formation is subsequently initiated by osteoblasts, which produced type I collagen and other proteins, such as osteocalcin, which then form osteoid, a substrate for which mineralization can occur. The newly formed osteoid then begins to accumulate matrix molecules and mineralize.²² In healthy adults, bone resorption and formation is a tightly balanced process. Both high or low rates of remodeling with an imbalanced bone resorption and formation can be associated with decreased or increased bone mass.

The synthesis of type I collagen during the bone formation phase involves the intertwining of one alpha-2 and two alpha-1 polypeptide chains to form a helical structure known as procollagen, followed by cleavage of their amino-terminal and carboxy-terminal peptides to form tropocollagen. The N-telopeptide (NTX) is the pyridinoline crosslink in the N-telopeptide region that joins alpha-1 chains to alpha-2 chains,²⁵ whereas the C-telopeptide (CTX) is a fragment of the alpha-1 peptide with an isomerized bond between the aspartate and the glycine from the carboxyterminal region.²⁶ NTX and CTX, together with the bone-specific alkaline phosphatase and amino terminal propeptide of type 1 procollagen (P1NP) are the most clinically useful markers of bone turnover.^{27,28} Osteoblasts produce osteocalcin, which is also used as a marker of bone formation.²⁹ Furthermore, bone resorption results in the release of bone mineral and the collagen-rich osteoid, whereas osteoid formation involves the production of the byproducts of collagen and other proteins. These substances may be released in the circulation, and can be measured in serum and urine to provide information on the rate of bone resorption and formation, and are collectively termed in the clinic as "bone turnover markers" (BTM)²³ (Table 1).

Fracture Risk and Diabetes Mellitus

Fracture risk is significantly higher in both T1DM and T2DM populations when compared to the general population.² The incidence of hip fracture in individuals with T1DM were reported to be six times higher than in the population (mean age 65 years) and 2,5-fold higher than in the T2DM population.³

T1DM

A meta-analysis of 5 studies reported that T1DM is associated with an overall relative risk (RR) of 8,9 (95% CI 7,1–11,2) for hip fractures when compared with an age-matched nondiabetic population.² Most studies in young and older, male and female individuals with T1DM reported a decrease in BMD at the radius and femur.^{30–38} This decrease ranges from 22 to 37%.⁵ Individuals with T1DM showed decreased trabecular

and/or cortical volumetric BMD at the distal radius or tibia compared with non-diabetic controls,^{30,39–43} and some studies reported the associations of these alterations with poor glycemic control.^{40, 41}

T2DM

The risk of hip fracture is particularly increased in individuals with T2DM.^{21,44,45} The risk is even higher in those treated with insulin^{3,46} and poor glycemic control,⁴⁷ as reflected by high HbA_{1c} levels, which may indicate the more advanced disease state. Studies have also reported increased fracture risk in individuals with more hypoglycemic episodes.⁴⁸ A meta-analysis of four cohorts showed that the RR of hip fractures reached 2,7 (95% CI, 1,7–4,4).² The risks for other fractures appear to also increase in T2DM compared to healthy individuals, such as fractures of the wrist⁴⁹ and foot,^{21,50} as well as of the vertebrae.⁴

Although earlier studies reported lower or unchanged BMD, recent large studies found that in T2DM, in contrast with T1DM, BMD is increased when compared to controls.^{20,49, 51–60} Furthermore, this increase in BMD remained after adjustment for body weight and composition,^{55, 60} and ranges between 5 to 10% above age-matched, non-diabetic controls.⁵⁰ Bone fragility depends not only on the reduction in bone mineral mass, as reflected by BMD, but also from changes to the bone microstructure and the components of the bone material. This is likely to account for the increased risk of fracture despite the increased BMD seen in individuals with T2DM. Indeed, MRI studies revealed greater cortical porosity in individuals with T2DM compared with non-diabetic controls,^{61,62} a finding repeated by a study using quantitative CT (Xtreme-CT), especially in those with fractures and/or microvascular complications.^{6–9} Recent diagnostic advances enable the measurement of *in vivo* bone material strength (BMS) by the minimally invasive, bone microindentation testing.^{7,63} Postmenopausal women with T2DM demonstrated lower BMS and greater radial cortical porosity. Poor BMS was correlated with poor long-term glycemic control over the past 10 years.⁷ A study in a similar population with fragility fractures suggests that severe deficits in cortical bone quality, as depicted by an increase in porosity, is a likely cause of fragility fractures.⁸ Regardless of the difference in BMD alterations between T1DM and T2DM, DM alone has been shown to be predictive of increased post-fracture mortality risk during hospitalization⁶⁴ and up to one year after discharge^{65,66} in individuals with hip fracture.

Mechanisms of DM-induced Bone Fragility

The mechanisms of DM-induced bone fragility in T1DM and T2DM are complex and only partially overlap.⁶⁷ Individuals with T1DM are mainly experiencing β -cell failure and low levels of IGF1 which disrupt the function of osteoblasts during growth. As a result, low peak bone

mass can occur at a young age.⁶⁸ In contrast, individuals with T2DM developed bone fragility at a later stage of the disease, and consequently, at a later age due to the lack of

insulin, glucose toxicity, advanced glycation end products (AGEs), cytokines and adipokines that are affecting osteocyte, bone turnover and collagen.⁶⁹

Table 1. Bone turnover markers

Markers	Full name	Origin	Comment	Source of Variability		
				Renal	Liver	Circadian rhythm
Resorption						
u-CTX	Urinary carboxy-terminal cross-linking telopeptide of type I collagen	Osteoclastic hydrolysis of collagen, generated by cathepsin K	Requires adjustment to levels of urinary creatinine Specificity: collagen type I, with highest contribution probably from bone Changes in levels of u-CTX were reported in both T1DM and T2DM Pioglitazone is associated with increased levels of u-CTX ¹¹⁰			X
s-CTX	Serum carboxy-terminal cross-linking telopeptide of type I collagen	Osteoclastic hydrolysis of collagen, generated by cathepsin K	Source of variability: food consumed (so must be collected after an overnight fast) Changes in levels of s-CTX were reported in both T1DM and T2DM Pioglitazone is associated with increased levels of s-CTX ¹¹⁰	X	X	X
u-NTX	Urinary amino-terminal cross-linking telopeptide of type I collagen	Osteoclastic hydrolysis of collagen type I	Requires adjustment to levels of urinary creatinine Specificity: collagen type I, with highest contribution probably from bone Changes in levels of u-NTX were reported in both T1DM and T2DM Pioglitazone is associated with increased levels of u-NTX ¹¹⁰			X
s-NTX	Serum amino-terminal cross-linking telopeptide of type I collagen	Osteoclastic hydrolysis of collagen type I, generated by cathepsin K	Specificity: collagen type I, with highest contribution probably from bone Changes in levels of u-NTX were reported in both T1DM and T2DM Pioglitazone is associated with increased levels of s-NTX ¹¹⁰	X		X
s-ICTP or CTX-MMP	Carboxy-terminal crosslinking telopeptide of type I collagen	Osteoclastic hydrolysis of collagen generated by matrix metalloproteinases	Specificity: collagen type I, with highest contribution probably from bone Marker is not responsive to usual treatments for osteoporosis Lower s-PICP to s-ICTP ratio were reported in T2DM ¹² Troglitazone use in T2DM individuals is associated with a decrease in s-ICTP ¹¹¹	X	X	X
u-DPD	Urinary deoxypyridinoline	Proteolytic hydrolysis of collagen, found in bone	Requires adjustment to levels of urinary creatinine Specificity: highest contribution from bone Sources of variability: UV radiation Changes in levels of u-DPD were reported in both T1DM and T2DM ¹¹² Troglitazone use in T2DM individuals is associated with a decrease in u-DPD ¹¹¹			X
u-PYD	Urinary pyridinoline	Found in bone, cartilage, tendon, blood vessels	Requires adjustment to urinary creatinine Specificity: highest contribution from bone and cartilage Sources of variability: active arthritis and UV radiation		X	X
s-TRAP	Serum tartrate-resistant acid phosphatase	Includes two isoforms: type 5a (platelets, erythrocytes and other sources) and type 5b (osteoclasts)	Sources of variability: influenced by haemolysis and blood clotting Changes in levels of s-OC were reported in both T1DM and T2DM ¹¹² Levels of s-TRAP is affected by long-term use of insulin in T1DM ³⁶			X
Formation						
s-OC	Serum osteocalcin	Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts	Specificity: specific marker of osteoblast function Rapid degradation in serum may lead to heterogeneity of OC fragments measured Sources of variability: large inter-laboratory variation Changes in levels of s-OC were reported in both T1DM and T2DM	X		X
u-OC	Urinary osteocalcin	Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts	Adjusted to levels of urinary creatinine (/Cr) Specificity: specific marker of osteoblast function Changes in levels of u-OC were reported in non-insulin dependent DM ¹¹²	X		X
s-ALP	Serum alkaline phosphatase (total)	Ubiquitous, membrane bound tetrameric enzyme located on the outer cell surface of various tissues: liver, bone, intestine, spleen, kidney and placenta	Specificity: non-specific for bone (about 50% is liver isoform in healthy individuals) Changes in levels of s-ALP were reported in both T1DM and T2DM Troglitazone use in T2DM individuals is associated with a decrease in s-ALP ¹¹¹			X
s-BALP	Serum bone-specific alkaline phosphatase	Ubiquitous, membrane bound tetrameric enzyme located on the outer cell surface of osteoblasts	Specificity: specific for bone, but with some cross-reactivity with liver isoform (up to 20%) Changes in levels of s-BALP were reported in T2DM ¹¹² Troglitazone use in T2DM individuals is associated with a decrease in s-BALP ¹¹¹			X
s-PICP	Procollagen type I C propeptide	Precursor molecules of collagen type I synthesised by osteoblasts	Specificity: mostly derived from bone collagen type I (around 90%). Short serum half-life. Regulated by hormones (thyroid, IGF-1) Lower s-PICP to s-ICTP ratio were reported in T2DM ¹²			X
s-PINP	Procollagen type I N propeptide	Precursor molecules of collagen type I synthesised by osteoblasts	Specificity: mostly derived from bone collagen type I A ssay: may recognise trimer alone (intact) or trimer and monomer (total PINP) Changes in levels of s-P1NP were reported in both T1DM and T2DM			X

Adapted from Vasikaran et al.¹⁰⁹

Table 2. Studies reporting on bone turnover in individuals with DM

Study author	Participants	BTM measured	Comments
Reyes-Garcia et al.; 2013 ¹¹⁰	78 T2D (43 men, 35 women), 55 controls	OC (ns)- RIA (DiaSorin, Stillwater, Minnesota USA; normal range 1.8–6.6 ng/ml, CTX ↓ EIA (Elecys β CrossLaps, Roche Diagnostics SL, Barcelona, Spain; normal range 0.01–6 ng/ml)	Vertebral fractures in 27.7% of T2D and 21.7% of controls Cross-sectional
Yamamoto et al.; 2012 ¹¹¹	255 T2D (postmenopausal women and men), 240 controls	OC↓, CTX↓ (electrochemiluminescence immunoassay on an automated analyzer; Roche Diagnostics GmbH, Mannheim, Germany), PTH↓	Excluded if serum creatinine was higher than normal range
Manavalan et al.; 2012 ¹¹²	18 T2D PM, 27 controls PM	OC↓, ELISA (IDS), CTX ↓ ELISA	At least 1 year use of antidiabetic medication eGFR < 60 ml/min excluded Renal disease excluded Case-control
Bhattoa et al.; 2013 ¹¹³	68 male T2D, 68 male controls	OC↓, CTX↓ electrochemiluminescence immunoassay (Roche Diagnostics GmbH, Mannheim, Germany).	Renal disease excluded Case-control
Ardawi et al.; 2013 ¹¹⁴	482 T2D PM women, 482 controls PM	LIASON autoanalyzer (DiaSorin Inc., Stillwater, MN, USA)	VF in 24.5% of T2D and none in controls
Hamilton et al.; 2012 ¹¹⁵	26 T1D, 27 T2D	CTX ↑, OC (ns), PTH (ns)	
Akin et al.; 2003 ¹¹⁶	57 T2D PM, 20 controls PM	OC↓, NTX↓	BMI significantly lower in controls, fasting, chronic disease excluded
Reyes-Garcia et al.; 2013 ¹¹⁰	78 T2D, 55 controls	CTX↓, PTH↓, enzyme immunoassay (EIA) and ELISA	Vertebral fractures in 27.7% of T2D and 21.7% of controls Renal disease excluded
Jiajue et al.; 2014 ¹¹⁷	236 T2D PM, 1055 controls PM	CTX↓, P1NP↓	Stage 4 and 5 chronic kidney diseases excluded
Farr et al.; 2014 ⁷	30 T2D PM, 30 controls PM	CTX↓, P1NP↓	MI significantly lower in controls. Performs microindentation
Manavalan et al.; 2012 ¹¹²	18 T2D PM, 27 controls PM	Circulating OC(+) cells ↓	At least 1 year use of antidiabetic medication eGFR < 60 ml/min excluded Renal disease excluded
Bhattoa et al.; 2013 ¹¹⁸	68 male T2D, 68 male controls	OC↓, CTX↓	Renal disease excluded
Gaudio et al.; 2012 ¹¹⁹	40 T2D PM, 40 controls PM	CTX↓	Renal bone disease excluded
Ardawi et al.; 2013 ¹¹⁴	482 T2D PM, 482 controls PM	IGF-1↓, sclerostin ↑, OC↓, CTX↓, P1NP↓, NTX↓	VF in 24.5% of T2D and none in controls
Hernandez et al.; 2013 ¹²⁰	2431 subjects of these 45 T2D	CTX and P1NP↓ in T2DM individuals who use statins	PM females and older men, Coexisting medical disorder that might affect bone metabolism was excluded. T2D was newly diagnosed.
Sarkar and Choudhury; 2013 ¹²¹	108 T2D, 50 controls	OC↓	
Movahed et al.; 2012 ¹²²	382 PM of these 102 T2D	OC↓, CTX↓	The diabetes group is a subgroup of the total population. No renal disorders
Sosa et al.; 1996 ¹²³	47 female NIDDM, 252 female controls	OC (ns), ALP (ns)	
Chen et al.; 2013 ¹²⁴	55 T2D, 27 controls	Plasma ALP↑, OC↓	No history of metabolic bone disease

Alkaline phosphatase (ALP), C-terminal cross-link of collagen (CTX), estimated glomerular filtration rate (eGFR), insulin-like growth factor-1 (IGF-1), myocardial infarction (MI), Non-insulin dependent diabetes mellitus (NIDDM), not significant (ns), osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP), postmenopausal (PM), parathyroid hormone (PTH), type 1 diabetes (T1D), type 2 diabetes (T2D), vertebral fracture (VF),

Low Bone Turnover

Most published studies in individuals with DM have reported low bone turnover (Table 2). Osteocalcin level, a marker of bone formation, is decreased in both T1DM and T2DM,⁷⁰⁻⁷² and is negatively correlated with HBA_{1c} level.⁷⁰ The negative correlation with HBA_{1c} was also reported for CTX, a marker of bone resorption.⁷⁰ When looking separately at T1DM and T2DM, osteocalcin levels have been reported to be decreased in T1DM and only borderline significantly decreased in T2DM.⁷³ Similarly, P1NP and NTX also tended to be lower in individuals with DM.⁵ Consistently, histological study of DM found decreased number of osteoblasts and osteoid.⁷⁴ In general, the processes involved in the decreased bone formation in T2DM include a decrease in bone quality, alterations of the mesenchymal cell differentiation and bone microcirculation, as well as changes in osteoblasts and osteoclasts (Figure 1).

Adipokines

Adiponectin, a protein hormone secreted by adipose tissue, was found to be decreased in T2DM.⁷⁵ Adiponectin was reported to have an anabolic effect on osteoblasts and inhibits osteoclastic activity *in vitro*.⁷⁶ However, clinical studies reported conflicting findings on whether there were negative correlations between adiponectin levels and

BMD in individuals with T2DM. Leptin, another adipokine which is secreted by white adipose, bone marrow adipocytes and osteoblastic cells, was found to be lower in individuals with DM compared with controls. A negative correlation between leptin and NTX was found in individuals with T2DM, whereas a positive correlation was found with leptin and Z-scores at the distal radius, but not at the femoral neck or lumbar spine.⁷⁷ Interestingly, *in vitro* and animal studies showed that high glucose level increases the expression of adipogenic markers such as the peroxisome proliferator-activated receptor (PPAR)- γ , adipocyte fatty acid binding protein (aP2), resistin and adiponectin, whereas it suppresses cell growth, mineralization, and expression of osteogenic markers including Runx2, collagen I, osteocalcin, osteonectin.^{78,79} Further studies are needed to precisely explain the role of adiponectins in affecting bone fragility.

Advanced Glycation End Products (AGEs)

Individuals with DM have increased levels of AGEs due to hyperglycemia and increased levels of oxidative stress.⁸⁰ The main mechanisms by which AGEs contribute to damaging the bone tissue are: 1) by forming cross-links with target protein, permanently altering cellular structure, and 2) by interacting with specific receptors to increase oxidative stress and inflammation.⁸¹ The receptor




Figure 1. Process involved in the decrease of bone turnover and increase of fracture risk.

for AGEs (RAGE) initiates the intracellular signaling through the binding of AGEs.⁸² The soluble isoform of RAGE (known as soluble RAGE, sRAGE) is thought to be produced by proteolytic cleavage of disintegrin and metalloproteinase domain-containing proteins (ADAMs). Activation of the RAGE signaling pathway leads to a positive feedback loop by enhancing the NF- κ B expression. Subsequently, important inflammatory mediators, including tumor necrosis factor- α (TNF- α), interleukin-1 (IL-1), IL-6, and C-reactive protein (CRP) are upregulated through both AGE- and NF- κ B-mediated pathways.⁸² Increased AGE concentration is negatively associated with bone density and mineralization,⁸³ and the cross-linking of AGE with collagen alters the mechanical properties of bone, disrupting its remodeling, increasing its stiffness and fragility.⁸⁴⁻⁸⁶ Pentosidine, a well-known AGE, was also shown to disrupt osteoblast differentiation.⁸⁷ Studies found that poor glycemic control was associated with increased risk of fractures in individuals with DM, and suggest that HbA_{1c} level of <8% could reduce fracture risk in individuals with DM.

Insulin and IGF1

Insulin exerts an anabolic effect on bones by promoting osteoblast proliferation and differentiation.⁸⁸ Animal studies have shown that diabetic rodents have impaired bone formation following bone injury whereas insulin injection normalized it.⁸⁹ Insulin deficiency, as in T1DM, is characterized by low levels or activity of insulin-like growth factor 1 (IGF1). The stimulating activity of IGF1 on osteoblasts is inhibited by high concentration of AGEs or glucose.^{90,91} In contrast with T1DM, T2DM is a disease that mainly shows insulin resistance. It remains unclear how in T2DM insulin resistance and insulin deficiency at its later stage may affect bone metabolism and fragility.

Pro-inflammatory cytokines

Pro-inflammatory cytokines have been implicated in both T1DM and T2DM and in the development of complications of both diseases. Elevated pro-inflammatory cytokine levels, such as TNF and IL-6, can activate osteoclastogenesis and inhibit osteoblast differentiation.^{92,93} Indirectly, the reactive oxygen species generated due to the exposure of tissue to IL-1, IL-6 and TNF can affect the differentiation and survival of osteoclasts, osteoblasts, and osteocytes.

Glucose-lowering Drugs and Bone Metabolism

Antidiabetic treatment is aimed at achieving good glucose control to reduce the risk of complications. Data showed that 1% reduction in HbA_{1c} levels led to 37% reduction in microvascular complication endpoints.⁹⁴ As HbA_{1c}, microvascular complications and bone fragility have been shown to be interrelated, it is reasonable to consider that optimal glucose control may reduce fracture risk. Individuals with poor glycemic control have increased risk for fractures.^{47,95,96} In individuals with T2DM, HbA_{1c} levels $\geq 7,5\%$ were reported to have 62% higher risk for fractures compared to those with HbA_{1c} levels <7,5%. The ACCORD trial reported that there was no substantial benefit for fracture prevention or BMD changes in lowering HbA_{1c} below 7,5%.

Insulin was shown to increase the risk of falls in insulin-treated individuals if their HbA_{1c} levels were $\leq 6\%$. It appeared that more aggressive glycemic control in elderly individuals with long term disease might increase hypoglycemic events and thus the risk for falls and fractures.⁹⁷ Metformin, the first line drug for DM, was found from most clinical studies to have positive or

neutral effect on BMD and fracture risk in large cohorts.^{46,98,99} Sulfonylureas show neutral effect on BTM levels, and studies on its clinical effect has not been established.⁴⁶ However, sulfonylureas should be avoided in individuals at risk for bone fragility due to its risk for inducing hypoglycemic events.^{67,100} Thiazolidinediones, which includes rosiglitazone and pioglitazone, activate peroxisome proliferator-activated receptors (PPARs), particularly PPAR- γ . *In vitro* and *in vivo* studies show increased adipogenesis and impaired osteoblastogenesis. Meta-analyses confirmed an increased risk for fractures (OR 2.23, 95% CI 1.65–3.01¹⁰¹ and OR=1.94; 95%CI: 1.60–2.35¹⁰²) in women treated with pioglitazone or rosiglitazone, but not in men. The evidence on the incretin-based treatments, GLP1 analogues and DPP4 inhibitors, are less conclusive.⁶⁷ A meta-analysis found that two different GLP1 analogues, liraglutide and exenatide, had protective and negative effects, respectively, on fracture risk. However, these studies were not designed for bone outcomes and differ in their design and power.¹⁰³ Studies on DPP4 inhibitors also did not find consistent effects on fracture outcomes.^{104,105} Sodium/glucose co-transporter 2 (SGLT2) inhibitors are new generation antidiabetics which exert effects by inhibiting glucose reabsorption in the proximal tubule of the kidney.¹⁰⁶ Data has also not been consistent in this group of drugs. While dapagliflozin and empagliflozin seem to have a neutral effect on bone turnover and BMD parameters, canagliflozin was reported to cause bone loss at the hips^{107,108} and increase the risk for hip fractures.

CONCLUSIONS

Fracture risk is known to be increased in both T1DM and T2DM. Levels of BTM were also lower in individuals with DM compared to non-DM controls. Despite increasing data on the association between BMD, BTM and fracture in individuals with DM, there are still challenges in identifying those with high fracture risk. Oxidative stress, inflammation and the production of AGEs increase the risk of complications. Additionally, disturbances in bone collagen metabolism and bone mineralization also reduce bone strength, while altered fat metabolism also affects bone health. A population of individuals are treated with insulin, but its use has been associated with increased fracture risk.⁴⁶ It remains unclear whether insulin use is merely a marker for the severity or duration of disease, or induces more hypoglycemic events that lead to falls. Furthermore, it is unknown whether in DM, changes in bone metabolism occurs earlier in the disease course. It is therefore important to consider the treatment approach and education of fall prevention in these individuals who are already at increased risk for fractures. Medications with favorable effect on bone metabolism such as metformin or incretin-based treatments may be the preferred treatment while thiazolidinediones should be used with careful evaluation and patient education. Evaluation by use of BTM may be of benefit, but needs

further studies in particular populations of individuals with DM such as premenopausal women or the Indonesian population.

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

The authors received research grant from Hibah Penelitian Unggulan Perguruan Tinggi (PUPT) from the Directorate of Research and Public Services, Ministry of Research, Technology and Higher Education.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 7th ed, 2015.
2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. *Am J Epidemiol.* 2007;166(5):495-505. PMID: 17575306. <https://doi.org/10.1093/aje/kwm106>.
3. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: The nurses' health study. *Diabetes Care.* 2006;29(7):1573-8. PMID: 16801581. <https://doi.org/10.2337/dc06-0440>.
4. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. *J Bone Miner Res.* 2009;24(4):702-9. PMID: 19049338. <https://doi.org/10.1359/jbmr.081207>.
5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes -- a meta-analysis. *Osteoporos Int.* 2007;18(4):427-44. PMID: 17068657. <https://doi.org/10.1007/s00198-006-0253-4>.
6. Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2010;95(11):5045-55. PMID: 20719835. PMCID: PMC2968722. <https://doi.org/10.1210/jc.2010-0226>.
7. Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. *J Bone Miner Res.* 2014;29(4):787-95. PMID: 24123088. PMCID: PMC3961509. <https://doi.org/10.1002/jbmr.2106>.
8. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. *J Bone Miner Res.* 2013;28(2):313-24. PMID: 22991256. PMCID: PMC3534818. <https://doi.org/10.1002/jbmr.1763>.
9. Shanbhogue VV, Hansen S, Frost M, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. *Eur J Endocrinol.* 2016;174(2):115-24. PMID: 26537860. <https://doi.org/10.1530/EJE-15-0860>.
10. Muñoz-Torres M, Jódar E, Escobar-Jiménez F, López-Ibarra PJ, Luna JD. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. *Calcif Tissue Int.* 1996;58(5):316-9. PMID: 8661964.
11. Miazgowski T, Czekalski S. A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. *Osteoporos Int.* 1998;8(5):399-403. PMID: 9850345. <https://doi.org/10.1007/s001980050082>.
12. Jehle PM, Jehle DR, Mohan S, Böhm BO. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. *J Endocrinol.* 1998;159(2):297-306. PMID: 9795371.
13. Tuominen JT, Impivaara O, Puukka P, Rönnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. *Diabetes Care.* 1999;22(7):1196-200. PMID: 10388989.
14. Gallacher SJ, Fenner JA, Fisher BM, et al. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. *Diabet Med.* 1993;10(2):129-33. PMID: 8096168.

15. Weber G, Beccaria L, de'Angelis M, et al. Bone mass in young patients with type I diabetes. *Bone Miner.* 1990;8(1):23-30. PMID: 2306551.
16. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. *N Engl J Med.* 1995;332(12):767-73. PMID: 7862179. <https://doi.org/10.1056/NEJM19950323321202>.
17. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountains Eye Study. Diabetes and risk of fracture: The Blue Mountains Eye Study. *Diabetes Care.* 2001;24(7):1198-203. PMID: 11423502.
18. Nicodemus KK, Folsom AR; Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. *Diabetes Care.* 2001;24(7):1192-7. PMID: 11423501.
19. Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T. Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. *Bone.* 1993;14(1):29-33. PMID: 8442999.
20. van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. *Ann Intern Med.* 1995;122(6):409-14. PMID: 7856988.
21. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: A prospective study. *J Clin Endocrinol Metab.* 2001;86(1):32-8. PMID: 11231974. <https://doi.org/10.1210/jcem.86.1.7139>.
22. Hadjidakis DJ, Androulakis II. Bone remodeling. *Ann N Y Acad Sci.* 2006;1092:385-96. PMID: 17308163. <https://doi.org/10.1196/annals.1365.035>.
23. Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. *Rheum Dis Clin North Am.* 1994;20(3):589-607. PMID: 7984780.
24. McKee MD, Nanci A. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: Ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. *Microsc Res Tech.* 1996;33(2):141-64. PMID: 8845514. [https://doi.org/10.1002/\(SICI\)1097-0029\(19960201\)33:2<141::AID-JEMT5>3.0.CO;2-W](https://doi.org/10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W).
25. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. *J Bone Miner Res.* 1992;7(11):1251-8. PMID: 1466251.
26. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. *Clin Chem.* 1998;44(11):2290-300. PMID: 9799756.
27. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. *Osteoporos Int.* 2000;11(4):295-303. PMID: 10928218. <https://doi.org/10.1007/PL00004183>.
28. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. *J Bone Miner Res.* 1998;13(7):1124-33. PMID: 9661076. <https://doi.org/10.1359/jbmr.1998.13.7.1124>.
29. Seibel MJ. Biochemical markers of bone turnover part I: Biochemistry and variability. *Clin Biochem Rev.* 2005;26(4):97-122. PMID: 16648882. PMID: PMC1320175.
30. Forst T, Beyer J, Pfützner A, et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. *Diabet Med.* 1995;12(10):874-9. PMID: 8846677.
31. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. *J Endocrinol Invest.* 2000;23(5):295-303. PMID: 10882147. <https://doi.org/10.1007/BF03343726>.
32. Hadjidakis DJ, Raptis AE, Sfakianakis M, Mylonakis A, Raptis SA. Bone mineral density of both genders in type 1 diabetes according to bone composition. *J Diabetes Complications.* 2006;20(5):302-7. PMID: 16949517. <https://doi.org/10.1016/j.jdiacomp.2005.07.006>.
33. Strotmeyer ES, Cauley JA, Orchard TJ, Steenkiste AR, Dorman JS. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. *Diabetes Care.* 2006;29(2):306-11. PMID: 16443878.
34. Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T. Young women with type 1 diabetes have lower bone mineral density that persists over time. *Diabetes Care.* 2008;31(9):1729-35. PMID: 18591404. PMID: PMC2518333. <https://doi.org/10.2337/dc07-2426>.
35. Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo M, García-Cervigón AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: A prospective study. *Osteoporos Int.* 2000;11(5):455-9. PMID: 10912849.
36. Eller-Vainicher C, Zhukouskaya VV, Tolkachev YV, et al. Low bone mineral density and its predictors in type 1 diabetic patients evaluated by the classic statistics and artificial neural network analysis. *Diabetes Care.* 2011;34(10):2186-91. PMID: 21852680. PMID: PMC3177712. <https://doi.org/10.2337/dc11-0764>.
37. Joshi A, Varthakavi P, Chadha M, Bhagwat N. A study of bone mineral density and its determinants in type 1 diabetes mellitus. *J Osteoporos.* 2013;2013:397814. PMID: 23607045. PMID: PMC3628496. <https://doi.org/10.1155/2013/397814>.
38. Soto N, Pruzzo R, Eyzaguirre F, et al. Bone mass and sex steroids in postmenarcheal adolescents and adult women with type 1 diabetes mellitus. *J Diabetes Complications.* 2011;25(1):19-24. PMID: 19955005. <https://doi.org/10.1016/j.jdiacomp.2009.10.002>.
39. Bechtold S, Dirlenbach I, Raile K, Noelle V, Bonfig W, Schwarz HP. Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: Data using peripheral quantitative computed tomography. *Pediatrics.* 2006;118(3):e627-34. PMID: 16908617. <https://doi.org/10.1542/peds.2005-2193>.
40. Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. *Osteoporos Int.* 2009;20(6):923-33. PMID: 18830554. PMID: PMC2748939. <https://doi.org/10.1007/s00198-008-0763-3>.
41. Heap J, Murray MA, Miller SC, Jalili T, Moyer-Mileur LJ. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. *J Pediatr.* 2004;144(1):56-62. PMID: 14722519. <https://doi.org/10.1016/j.jpeds.2003.10.066>.
42. Lettgen B, Hauffa B, Möhlmann C, Jeken C, Reiners C. Bone mineral density in children and adolescents with juvenile diabetes: Selective measurement of bone mineral density of trabecular and cortical bone using peripheral quantitative computed tomography. *Horm Res.* 1995;43(5):173-5. PMID: 7782045.
43. Saha MT, Sievänen H, Salo MK, Tulokas S, Saha HH. Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers. *Osteoporos Int.* 2009;20(8):1401-6. PMID: 19083073. <https://doi.org/10.1007/s00198-008-0810-0>.
44. Forsén L, Meyer H, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trøndelag Health Survey. *Diabetologia.* 1999;42(8):920-5. PMID: 10491750. <https://doi.org/10.1007/s001250051248>.
45. Ahmed LA, Joakimsen RM, Berntsen GK, Fønnebø V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: The Tromsø study. *Osteoporos Int.* 2006;17(4):495-500. PMID: 16283065. <https://doi.org/10.1007/s00198-005-0013-x>.
46. Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: The MrOS study. *Diabetologia.* 2014;57(10):2057-65. PMID: 24908567. PMID: PMC4344350. <https://doi.org/10.1007/s00125-014-3289-6>.
47. Li CJ, Liu CS, Lin WY, et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: A competing risk analysis of Taiwan Diabetes Cohort Study. *J Bone Miner Res.* 2015;30(7):1338-46. PMID: 25598134. <https://doi.org/10.1002/jbmr.2462>.
48. Johnston S, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. *Diabetes Obes Metab.* 2012;14(7):634-43. PMID: 22335246. <https://doi.org/10.1111/j.1463-1326.2012.01583.x>.
49. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: The Rotterdam Study. *Osteoporos Int.* 2005;16(12):1713-20. PMID: 15940395. <https://doi.org/10.1007/s00198-005-1909-1>.
50. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, et al. Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study. *J Clin Endocrinol Metab.* 2006;91(9):3404-10. PMID: 16804043. <https://doi.org/10.1210/jc.2006-0614>.
51. Kwon DJ, Kim JH, Chung KW, et al. Bone mineral density of the spine using dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. *J Obstet Gynaecol Res.* 1996;22(2):157-62. PMID: 8697346.

52. Pérez-Castrillón JL, De Luis D, Martín-Escudero JC, Asensio T, del Amo R, Izaola O. Non-insulin-dependent diabetes, bone mineral density, and cardiovascular risk factors. *J Diabetes Complications*. 2004;18(6):317-21. PMID: 15531180. [https://doi.org/10.1016/S1056-8727\(03\)00072-2](https://doi.org/10.1016/S1056-8727(03)00072-2).
53. Lunt M, Masaryk P, Scheidt-Nave C, et al. The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: The EVOS study. *Osteoporos Int*. 2001;12(8):688-98. PMID: 11580083.
54. Hanley D, Brown J, Tenenhouse A, et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: Cross-sectional results from the Canadian Multicentre Osteoporosis Study. *J Bone Miner Res*. 2003;18(4):784-90. PMID: 12674340. <https://doi.org/10.1359/jbmr.2003.18.4.784>.
55. Dennison E, Syddall H, Sayer AA, Craighead S, Phillips D, Cooper C. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: Evidence for an indirect effect of insulin resistance? *Diabetologia*. 2004;47(11):1963-8. PMID: 15565368. <https://doi.org/10.1007/s00125-004-1560-y>.
56. Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. *JAMA*. 1992;268(23):3333-7. PMID: 1453525.
57. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. *Osteoporos Int*. 2005;16(12):1506-12. PMID: 15824889. <https://doi.org/10.1007/s00198-005-1877-5>.
58. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. *J Bone Miner Res*. 2005;20(4):596-603. PMID: 15765178. <https://doi.org/10.1359/JBMR.041219>.
59. Dobnig H, Piswanger-Solkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. *J Clin Endocrinol Metab*. 2006;91(9):3355-63. PMID: 16735485. <https://doi.org/10.1210/jc.2006-0460>.
60. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. *J Bone Miner Res*. 2004;19(7):1084-91. PMID: 15176990. <https://doi.org/10.1359/JBMR.040311>.
61. Pritchard JM, Giangregorio LM, Atkinson SA, et al. Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: A two year longitudinal study. *BMC Musculoskelet Disord*. 2013;14:114. PMID: 23530948. PMID: PMC3618189. <https://doi.org/10.1186/1471-2474-14-114>.
62. Pritchard JM, Giangregorio LM, Atkinson SA, et al. Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. *Arthritis Care Res (Hoboken)*. 2012;64(1):83-91. PMID: 22213724. PMID: PMC5096917. <https://doi.org/10.1002/acr.20602>.
63. Randall C, Bridges D, Guerri R, et al. Applications of a new handheld reference point indentation instrument measuring bone material strength. *J Med Device*. 2013;7(4):0410051-6. PMID: 24115973. PMID: PMC3792445. <https://doi.org/10.1115/1.4024829>.
64. Dubey A, Aharonoff GB, Zuckerman JD, Koval KJ. The effects of diabetes on outcome after hip fracture. *Bull Hosp Jt Dis*. 2000;59(2):94-8. PMID: 10983258.
65. Huang YF, Shyu YI, Liang J, Chen MC, Cheng HS, Wu CC. Diabetes and health outcomes among older Taiwanese with hip fracture. *Rejuvenation Res*. 2012;15(5):476-82. PMID: 22998328. <https://doi.org/10.1089/rej.2011.1308>.
66. Muraki S, Yamamoto S, Ishibashi H, Nakamura K. Factors associated with mortality following hip fracture in Japan. *J Bone Miner Metab*. 2006;24(2):100-4. PMID: 16502115. <https://doi.org/10.1007/s00774-005-0654-z>.
67. Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. *Nat Rev Endocrinol*. 2017;13(4):208-19. PMID: 27658727. <https://doi.org/10.1038/nrendo.2016.153>.
68. Hough FS, Pierroz DD, Cooper C, Ferrari SL; IOF CSA Bone and Diabetes Working Group. Mechanisms in endocrinology: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. *Eur J Endocrinol*. 2016;174(4):R127-38. PMID: 26537861. <https://doi.org/10.1530/EJE-15-0820>.
69. Napoli N, Strollo R, Paladini A, Briganti SI, Pozzilli P, Epstein S. The alliance of mesenchymal stem cells, bone, and diabetes. *Int J Endocrinol*. 2014;2014:690783. PMID: 25140176. PMID: PMC4124651. <https://doi.org/10.1155/2014/690783>.
70. Maggio AB, Ferrari S, Kraenzlin M, et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. *J Pediatr Endocrinol Metab*. 2010;23(7):697-707. PMID: 20857842.
71. Adami S. Bone health in diabetes: Considerations for clinical management. *Curr Med Res Opin*. 2009;25(5):1057-72. PMID: 19292601. <https://doi.org/10.1185/03007990902801147>.
72. Díaz-López A, Bulló M, Juanola-Falgarona M, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: A nested case-control study. *J Clin Endocrinol Metab*. 2013;98(11):4524-31. PMID: 24037881. <https://doi.org/10.1210/jc.2013-2472>.
73. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. *Osteoporos Int*. 2014;25(6):1697-708. PMID: 24676844. <https://doi.org/10.1007/s00198-014-2676-7>.
74. Leite Duarte ME, da Silva RD. Histomorphometric analysis of the bone tissue in patients with non-insulin-dependent diabetes (DMNID). *Rev Hosp Clin Fac Med Sao Paulo*. 1995;51(1):7-11. PMID: 8762647.
75. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab*. 2001;86(5):1930-5. PMID: 11344187. <https://doi.org/10.1210/jcem.86.5.7463>.
76. Williams GA, Wang Y, Callon KE, et al. In vitro and in vivo effects of adiponectin on bone. *Endocrinology*. 2009;150(8):3603-10. PMID: 19406946. <https://doi.org/10.1210/en.2008-1639>.
77. Tamura T, Yoneda M, Yamane K, et al. Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. *Metabolism*. 2007;56(5):623-8. PMID: 17445536. <https://doi.org/10.1016/j.metabol.2006.12.008>.
78. Wang W, Zhang X, Zheng J, Yang J. High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. *Mol Cell Biochem*. 2010;338(1-2):115-22. PMID: 19949837. <https://doi.org/10.1007/s11010-009-0344-6>.
79. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. *Endocrinology*. 2005;146(8):3622-31. PMID: 15905321. PMID: PMC1242186. <https://doi.org/10.1210/en.2004-1677>.
80. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. *Am J Kidney Dis*. 1995;26(6):875-88. PMID: 7503061.
81. Geffer JV, Shaull AL, Fink MP, Delude RL. Comparison of distinct protein isoforms of the receptor for advanced glycation end-products expressed in murine tissues and cell lines. *Cell Tissue Res*. 2009;337(1):79-89. PMID: 19415334. <https://doi.org/10.1007/s00441-009-0791-0>.
82. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: From precursors to RAGE: Round and round we go. *Amino Acids*. 2012;42(4):1151-61. PMID: 20957395. PMID: PMC3062728. <https://doi.org/10.1007/s00726-010-0773-2>.
83. Odetti P, Rossi S, Monacelli F, et al. Advanced glycation end products and bone loss during aging. *Ann N Y Acad Sci*. 2005;1043:710-7. PMID: 16037297. <https://doi.org/10.1196/annals.1333.082>.
84. Hein GE. Glycation endproducts in osteoporosis—is there a pathophysiological importance? *Clin Chim Acta*. 2006;371(1-2):32-6. PMID: 16777084. <https://doi.org/10.1016/j.cca.2006.03.017>.
85. Dong XN, Qin A, Xu J, Wang X. In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption. *Bone*. 2011;49(2):174-83. PMID: 21530698. PMID: PMC3117937. <https://doi.org/10.1016/j.bone.2011.04.009>.
86. Tang S, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. *Bone*. 2007;40(4):1144-51. PMID: 17257914. PMID: PMC4398019. <https://doi.org/10.1016/j.bone.2006.12.056>.
87. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. *Ann N Y Acad Sci*.

- 2008;1126:166-72. PMID: 18448811. <https://doi.org/10.1196/annals.1433.044>.
88. Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. *Cell Biochem Funct.* 2010;28(4):334-41. PMID: 20517899. <https://doi.org/10.1002/cbf.1668>.
 89. Gandhi A, Beam HA, O'Connor JP, Parsons JR, Lin SS. The effects of local insulin delivery on diabetic fracture healing. *Bone.* 2005;37(4):482-90. PMID: 16027060. <https://doi.org/10.1016/j.bone.2005.04.039>.
 90. McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: Role in osteoblast development. *Acta Diabetol.* 2001;38(3):113-22. PMID: 11827431.
 91. Terada M, Inaba M, Yano Y, et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. *Bone.* 1998;22(1):17-23. PMID: 9437509.
 92. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor- α 1. *Endocrinology.* 2000;141(11):3956-64. PMID: 11089525. <https://doi.org/10.1210/endo.141.11.7739>.
 93. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNF α and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. *Cell Death Differ.* 2003;10(10):1165-77. PMID: 14502240. <https://doi.org/10.1038/sj.cdd.4401285>.
 94. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. *BMJ.* 2000;321(7258):405-12. PMID: 10938048. PMID: PMC27454.
 95. Oei L, Zillikens MC, Dehghan A, Buitendijk GH, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: The Rotterdam Study. *Diabetes Care.* 2013;36(6):1619-28. PMID: 23315602. PMID: PMC3661786. <https://doi.org/10.2337/dc12-1188>.
 96. Schneider AL, Williams EK, Brancati FL, Blecker S, Coresh J, Selvin E. Diabetes and risk of fracture-related hospitalization: The atherosclerosis risk in communities study. *Diabetes Care.* 2013;36(5):1153-8. PMID: 23248194. PMID: PMC3631877. <https://doi.org/10.2337/dc12-1168>.
 97. Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Diabetes-related complications, glycemic control, and falls in older adults. *Diabetes Care.* 2008;31(3):391-6. PMID: 18056893. PMID: PMC2288549. <https://doi.org/10.2337/dc07-1152>.
 98. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. *Diabetologia.* 2005;48(7):1292-9. PMID: 15909154. <https://doi.org/10.1007/s00125-005-1786-3>.
 99. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Stürmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. *J Clin Endocrinol Metab.* 2009;94(8):2792-8. PMID: 19470635. PMID: PMC2730861. <https://doi.org/10.1210/jc.2008-2157>.
 100. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: A 2-year study. *Diabetes Obes Metab.* 2014;16(12):1239-46. PMID: 25132212. <https://doi.org/10.1111/dom.12377>.
 101. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *Can Med Assoc J.* 2009;180(1):32-9. PMID: 1907365. PMID: PMC2612065. <https://doi.org/10.1503/cmaj.080486>.
 102. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials. *Bone.* 2014;68:115-23. PMID: 25173606. <https://doi.org/10.1016/j.bone.2014.08.010>.
 103. Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: A meta-analysis of randomized controlled trials. *Endocrine.* 2015;48(1):107-15. PMID: 25074632. <https://doi.org/10.1007/s12020-014-0361-4>.
 104. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: A Meta-analysis of randomized clinical trials. *Diabetes Care* 2011 34(11): 2474-6. PMID: 22025784. PMID: PMC3198283. <https://doi.org/10.2337/dc11-1099>.
 105. Mosenzon O, Wei C, Davidson J, et al. Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. *Diabetes Care.* 2015;38(11):2142-50. PMID: 26358285. <https://doi.org/10.2337/dc15-1068>.
 106. DeFronzo R, Davidson J, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. *Diabetes Obes Metab.* 2012;14(1):5-14. PMID: 21955459. <https://doi.org/10.1111/j.1463-1326.2011.01511.x>.
 107. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. *J Clin Endocrinol Metab.* 2015;101(1):44-51. PMID: 26580234. PMID: PMC4701848. <https://doi.org/10.1210/jc.2015-1860>.
 108. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2015;101(1):157-66. PMID: 26580237. PMID: PMC4701850. <https://doi.org/10.1210/jc.2015-3167>.
 109. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. *Osteoporos Int.* 2011;22(2):391-420. PMID: 21184054. <https://doi.org/10.1007/s00198-010-1501-1>.
 110. Reyes-García R, Rozas-Moreno P, López-Gallardo G, et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. *Acta Diabetol.* 2013;50(1):47-52. PMID: 22042129. <https://doi.org/10.1007/s00592-011-0347-0>.
 111. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. *J Clin Endocrinol Metab.* 2012;97(4):1277-84. PMID: 22337915. <https://doi.org/10.1210/jc.2011-2537>.
 112. Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2012;97(9):3240-50. PMID: 22740707. PMID: PMC3431571. <https://doi.org/10.1210/jc.2012-1546>.
 113. Bhattoa HP, Wamwaki J, Kalina E, Foldesi R, Balogh A, Antal-Szalmás P. Serum sclerostin levels in healthy men over 50 years of age. *J Bone Miner Metab.* 2013;31(5):579-84. PMID: 23525828. <https://doi.org/10.1007/s00774-013-0451-z>.
 114. Ardawi MS, Akhbar DH, Alshaiikh A, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. *Bone.* 2013;56(2):355-62. PMID: 23845326. <https://doi.org/10.1016/j.bone.2013.06.029>.
 115. Hamilton EJ, Rakic V, Davis WA, et al. A five-year prospective study of bone mineral density in men and women with diabetes: The Fremantle Diabetes Study. *Acta Diabetol.* 2012;49(2):153-8. PMID: 21971710. <https://doi.org/10.1007/s00592-011-0324-7>.
 116. Akin O, Göl K, Aktürk M, Erkaya S. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. *Gynecol Endocrinol.* 2003;17(1):19-29. PMID: 12724015.
 117. Jiajie R, Jiang Y, Wang O, et al. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus. *Osteoporos Int.* 2014;25(8):1999-2005. PMID: 24760246. <https://doi.org/10.1007/s00198-014-2714-5>.
 118. Bhattoa HP, Onyeka U, Kalina E, et al. Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50 years of age with type 2 diabetes mellitus: A case-control study. *Clin Rheumatol.* 2013;32(8):1161-7. PMID: 23588883. <https://doi.org/10.1007/s10067-013-2254-y>.
 119. Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/ β -catenin signaling and reduced bone turnover in type 2 diabetes mellitus. *J Clin Endocrinol Metab.* 2012;97(10):3744-50. PMID: 22855334. <https://doi.org/10.1210/jc.2012-1901>.
 120. Hernández JL, Olmos JM, Romaña G, et al. Bone turnover markers in statin users: A population-based analysis from the Camargo Cohort Study. *Maturitas.* 2013;75(1):67-73. PMID: 23489550. <https://doi.org/10.1016/j.maturitas.2013.02.003>.
 121. Sarkar P, Choudhury A. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. *Eur Rev Med Pharmacol Sci.* 2013;17(12):1631-5. PMID: 23832730.
 122. Movahed A, Larjani B, Nabipour I, et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the

- metabolic syndrome components in postmenopausal women: The crosstalk between bone and energy metabolism. *J Bone Miner Metab.* 2012;30(6):683-91. PMID: 22752126. <https://doi.org/10.1007/s00774-012-0367-z>.
123. Sosa M, Dominguez M, Navarro MC, et al. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. *J Diabetes Complications.* 1996;10(4):201-5. PMID: 8835919.
124. Chen H, Li X, Yue R, Ren X, Zhang X, Ni A. The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients. *Diabetes Res Clin Pract.* 2013;100(2):272-6. PMID: 23522918. <https://doi.org/10.1016/j.diabres.2013.03.007>.

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that all the requirements for authorship have been met by each author, and that the final version of the manuscript has been read and approved by all authors; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere; (3) the Statement of Copyright Transfer [accepted manuscripts become the permanent property of the JAFES and are licensed with an Attribution-Share Alike-Non-Commercial Creative Commons License. Articles may be shared and adapted for non-commercial purposes as long as they are properly cited]; and the ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, authors declared that all means have been exhausted for securing such consent. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.



HERDIN
On Tour 2017

database.
information.connect.
full-text.quick. easy
health research. access.

☎ For inquiries contact: Kristine or Judy ☎ kmzamora@pchrd.dost.gov.ph
837-77534 loc (203)